ArticleAnnals of translational medicine2014
Circulating free DNA in the management of breast cancer.
Article in Annals of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03871790 (Peptide-based Immunization for Colon- and Pancreas-carcinoma), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol
Who cites it
19 citing papers in PubMed.
- Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer.Breast cancer research : BCR · 2025Article
- Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.Scientific reports · 2023Article
- Neutrophil extracellular traps predict postoperative pulmonary complications in paediatric patients undergoing parental liver transplantation.BMC gastroenterology · 2023Article
- Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS).Oncogene · 2023Article
- The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.Journal of translational medicine · 2022Article
- New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.Cancers · 2021Review
- Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review.Journal of clinical medicine · 2021Review
- Analysis of Serum Markers with Regard to Treatment Procedures in Advanced Stage Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Liquid biopsy for the detection and management of surgically resectable tumors.Langenbeck's archives of surgery · 2019Review
- Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.Cancer genetics · 2018Review
- HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.Breast cancer (Tokyo, Japan) · 2018Article
- Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.Frontiers in medicine · 2018Review
- TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-κB signaling pathways.Oncotarget · 2017Article
- Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.The American journal of case reports · 2017Article
- Liquid Biopsies for Cancer: Coming to a Patient near You.Journal of clinical medicine · 2017Review
- The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.Cancer management and research · 2017Review
- Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.NPJ breast cancer · 2017Article
- The number of tumorspheres cultured from peripheral blood is a predictor for presence of metastasis in patients with breast cancer.Oncotarget · 2016Article
- [Advances in Liquid Biopsy and its Clinical Application in the Diagnosis and Treatment of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Circulating cell-free DNA (cfDNA) is now under investigation as a "liquid biopsy" in the real time management of cancer. In The New England Journal of Medicine Dawson et al. reported a proof of concept investigation of tumour specific alterations in cfDNA and demonstrate that this fraction termed "circulating tumour DNA" (ctDNA) shows greater correlation with changes in tumour burden than two other circulating biomarkers (CA 15-3 and circulating tumor cell counts) in individuals with metastatic breast cancer receiving therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.